Nicofi Targets Selling E-Cigarette Users And Smokers On A Substitute
This article was originally published in The Tan Sheet
Executive Summary
Ross Myles Health is not making a smoking cessation or NRT claim for Nicofi sublingual tablets made with steam-extracted pure nicotine, keeping the product free of drug regulation by FDA. While Nicofi also is outside the agency’s current tobacco product authority, the firm is prepared for FDA oversight.
You may also be interested in...
E-Cigarettes Spark Evolution Of FDA’s Nicotine-Containing Medical Product Regulation
FDA’s tobacco, drug and medical device centers are discussing “some sort of jurisdictional policy” to “determine how to evolve the regulation of therapeutic nicotine products,” including OTC drugs, says tobacco program head Mitch Zeller.
Smoking Cessation Label Changes Could Lay Groundwork For Indications
FDA drops its requirement for labeling provisions for NRTs on duration of use and concomitant use of tobacco or other NRTs. Meanwhile, the agency rejects citizen petition requests for additional NRT indications, but says it is open to working with sponsors on developing those indications.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.